Nomura/Instinet Has Positive Read on Denali Therapeutics (DNLI) Amid Biogen's Aducanumab News
Tweet Send to a Friend
Nomura/Instinet analyst Christopher Marai reiterated a Buy rating and $35.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI) after Biogen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
